Johnson Investment Counsel Inc. significantly reduced its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 38.3% in the third quarter, with remaining holdings valued at $2.85 million. This reduction occurred despite Zimmer Biomet reporting strong fourth-quarter earnings, surpassing estimates with $2.42 EPS and $2.24 billion in revenue. The company also announced a new share repurchase program, signaling confidence in its future performance. Conversely, other institutional investors increased their positions in ZBH during the same period, indicating diverse investor strategies. These developments paint a mixed picture for the stock, combining a notable divestment by one key investor with positive signals from the company's earnings and buyback initiative. Analysts maintain an average 'Hold' rating for the stock, supporting a neutral to slightly positive outlook.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis